Lupin Ltd Analyst Rating
based on 35 analysts
40.00%
Buy
31.43%
Hold
28.57%
Sell
Based on 35 analysts offering long term price targets for Lupin Ltd. An average target of ₹1994.2
Source: S&P Global Market Intelligence
Lupin Ltd Share analysis
Lupin Ltd price forecast by 35 analysts
Downside of
High
₹2515
Target
₹1994.20
Low
₹1284
Lupin Ltd target price ₹1994.2, a slight downside of -7.45% compared to current price of ₹2224.5. According to 35 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.73%
Forecast
Actual
Including amortisation and stock based compensations
Lupin Ltd EPS growth forecast
EPS estimate Q1, FY2026:83.00%
Forecast
Actual
Source: S&P Global Market Intelligence
Lupin Ltd Performance
Day's Low
Day's High
₹2,158.65₹2,22952 Week's Low
52 Week's High
₹1,123₹2,312
| Returns % | |
| 1 Month Return | -2.48 % |
| 3 Month Return | + 18.56 % |
| 1 Year Return | + 85.77 % |
| Market Stats | |
| Previous Close | ₹2,154.65 |
| Open | ₹2,170.00 |
| Volume | 12.16L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹98,282.92Cr |
Lupin Ltd Key Statistics
| P/E Ratio | 43.35 |
| PEG Ratio | 1.53 |
| Market Cap | ₹98,282.92 Cr |
| P/B Ratio | 3.58 |
| EPS | 42.47 |
| Dividend Yield | 0.49 |
| Sector | Pharmaceuticals |
| ROE | 11.92 |
Lupin Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹98,282.92 Cr | 41.42% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹15,883.79 Cr | 3.46% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹85,895.67 Cr | 46.79% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹1,06,358.93 Cr | 71.87% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹60,333.85 Cr | 31.67% | 0.53 | NA | NA |
Lupin Ltd Mutual Fund Holdings
About Lupin Ltd
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Share Price: ₹2224.50 per share as on 11 Oct, 2024 04:01 PM
Market Capitalisation: ₹98,282.92Cr as of today
Revenue: ₹5,514.34Cr as on June 2024 (Q2 24)
Net Profit: ₹805.54Cr as on June 2024 (Q2 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Lupin Ltd
Lupin Shares Decline Amid Pharma Sector Drop - 10 Oct, 2024
On October 10, 2024, Lupin shares dropped 5.58% as part of a broader decline in the pharma sector, which saw the Nifty Pharma index fall 2%. Despite this, analysts noted potential for a bullish breakout in Lupin's stock.
Lupin Shares Decline After USFDA Observations - 07 Oct, 2024
Lupin Ltd's shares dropped 2% following the announcement of five observations from the USFDA after an inspection of its Pune biotech facility. The company is addressing these observations and plans to respond within the required timeframe.
Lupin Receives FDA Observations at Pune Facility - 05 Oct, 2024
Lupin Ltd's Pune biotech facility was inspected by the US FDA, resulting in five observations. The company reported a 76.01% increase in net profit for Q1 FY24.
Lupin Expands Portfolio and Projects Strong US Sales - 04 Oct, 2024
Lupin's subsidiary acquired nine brands in South Africa, while the company forecasts $200-225 million in US sales. Axis Securities sets a target price of Rs 2,500.
Lupin Partners with Scope, Faces USFDA Observations - 30 Sep, 2024
Lupin has entered a distribution agreement with Scope Ophthalmics to market eyecare products in Mexico. However, shares fell 1.75% due to USFDA observations at its Pithampur facility.
Lupin Faces FDA Observations at Pithampur Facility - 29 Sep, 2024
Lupin Ltd reported that the US FDA inspection of its Pithampur Unit-1 revealed three observations concerning both API and finished product manufacturing processes.
Lupin Faces USFDA Observations at Pithampur Facility - 28 Sep, 2024
Lupin Ltd received six observations from the USFDA following an inspection of its Pithampur facility. The company is addressing these observations and will respond promptly. Despite this, shares closed 1.6% higher, reflecting investor confidence.
Lupin Partners with Celnova Amid Sell Call - 27 Sep, 2024
Lupin faces a sell call targeting Rs 2,250 per share while announcing a partnership with Celnova Pharma to distribute NaMuscla in Argentina and Colombia, enhancing treatment for rare neuromuscular disorders.
Lupin Shares React to Patent Ruling Update - 20 Sep, 2024
Lupin shares are in focus following a favorable ruling from the US Court of Appeals regarding the Mirabegron patent. InCred Equities maintains a positive outlook, projecting significant revenue contributions from the drug in FY25 and FY26.
Lupin Secures License for Vonoprazan Tablets - 19 Sep, 2024
Lupin has entered a non-exclusive patent license agreement with Takeda to commercialize Vonoprazan tablets in India, branded as Lupivon. The drug, approved for treating gastric ulcers and related conditions, will enhance Lupin's gastroenterology portfolio in a market with high prevalence of acid peptic disorders.
Lupin Partners with Takeda for Vonoprazan Launch - 18 Sep, 2024
Lupin Limited has signed a non-exclusive patent license agreement with Takeda to market Vonoprazan tablets in India, enhancing its gastroenterology portfolio. The drug will be available in 10 mg and 20 mg strengths, approved for various acid peptic disorders.
Lupin Faces Challenges Amid New Launches - 16 Sep, 2024
Nomura highlights Lupin as a buying opportunity among Indian drugmakers, citing upcoming launches like PredForte. However, the company faces market share declines in some drugs and recent litigation losses.
Lupin Partners with Sunsure Energy for Solar Power - 13 Sep, 2024
Sunsure Energy has signed an agreement to supply 21MW of solar power to Lupin's Tarapur facility, enhancing Lupin's commitment to renewable energy and sustainability.
Lupin Expands Renewable Energy Investments - 12 Sep, 2024
Lupin has partnered with Sunsure Energy to supply 21 MW solar power and signed an agreement to acquire a 43% stake in Sunsure Solarpark, enhancing its commitment to sustainability.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 18.28% to 19.32% in Jun 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 4.99K Cr → 5.66K Cr (in ₹), with an average increase of 12.0% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 359.43 Cr → 801.31 Cr (in ₹), with an average increase of 55.1% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 126.7% return, outperforming this stock by 2.0%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 16.82% to 16.23% in Jun 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, LUPIN stock has moved down by -2.0%
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 47.01% to 46.98% in Jun 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.93% to 6.92% in Jun 2024 quarter
Lupin Ltd Infographics
Lupin Ltd Q1 FY2024-2025 Results: Key Insights
Lupin reports 8th consecutive quarters of EBITDA improvement in Q1FY25
Lupin Ltd Financials
Index Inclusions
Lupin Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.98% | ||
| Foreign Institutions | 19.32% | 5.65 | |
| Mutual Funds | 16.23% | ||
| Retail Investors | 6.92% | ||
| Others | 10.55% |
Lupin Ltd Key Indicators
Lupin Ltd Valuation
Lupin Ltd in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (43.35x)
October 10, 2024
Industry (58.96x)
October 10, 2024
Highest (517.33x)
December 2, 2022
Lupin Ltd Earnings and Dividends
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 77.18% since last year same period to ₹801.31Cr in the Q1 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 122.94% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.54%.
Read More about Dividends
Lupin Ltd Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Lupin Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Lupin Ltd shares.
Lupin Ltd (LUPIN) share price today is ₹2224.5
Lupin Ltd is listed on NSE
Lupin Ltd is listed on BSE
- Today’s highest price of Lupin Ltd is ₹2229.
- Today’s lowest price of Lupin Ltd is ₹2158.65.
PE Ratio of Lupin Ltd is 43.35
PE ratio = Lupin Ltd Market price per share / Lupin Ltd Earnings per share
Today’s traded volume of Lupin Ltd(LUPIN) is 12.16L.
Today’s market capitalisation of Lupin Ltd(LUPIN) is ₹98282.92Cr.
| Lupin Ltd(LUPIN | Price |
|---|---|
52 Week High | ₹2312 |
52 Week Low | ₹1123 |
Lupin Ltd(LUPIN) share price is ₹2224.5. It is down -3.78% from its 52 Week High price of ₹2312
Lupin Ltd(LUPIN) share price is ₹2224.5. It is up 98.09% from its 52 Week Low price of ₹1123
| Lupin Ltd(LUPIN | Returns |
|---|---|
1 Day Returns | 69.85% |
1 Month Returns | -2.48% |
3 Month Returns | 18.56% |
1 Year Returns | 85.77% |